Outpatient Clinic for Internal Medicine, Wels, Austria.
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):765-7. Epub 2012 Oct 17.
Published data were analysed to determine if the use of tumour necrosis factor (TNF) blocking agents in male patients during time of conception is associated with an increased risk of fetal abnormalities or complications during pregnancy. Moreover, we were interested in the impact of TNFblocking agents on sperm quality characteristics.
We performed a systematic literature review (Medline, online archives of Annual European Congress of Rheumatology and the American College of Rheumatology). One-hundred and thirty-nine Articles of potentially relevant reports were identified and screened for retrieval and nine articles were included in the final analysis.
Overall, there were sixty cases, where expectant fathers used TNFblocking agents shortly before conception. The outcomes of the pregnancies are documented in twenty-eight events. We did not find any documentation of miscarriages or physical abnormities associated with TNF blocking treatment and paternity; however, we did find documentation evidence that sperm motility and vitality even may improve under TNF-blocking therapy. This improvement may be caused by a decrease in disease activity.
Published data suggest that TNF-blocking therapy in male patients during time of conception does not increase the risk of adverse pregnancy outcome. In addition TNF-blocking therapy does not appear to reduce male fertility.
分析已发表的数据，以确定男性患者在受孕期间使用肿瘤坏死因子（TNF）阻滞剂是否会增加胎儿异常或妊娠并发症的风险。此外，我们还关注 TNF 阻滞剂对精子质量特征的影响。
我们进行了系统的文献回顾（Medline、欧洲风湿病学会年会在线档案和美国风湿病学会）。确定了 139 篇可能相关报告的文章，并进行了检索筛选，最终有 9 篇文章纳入了最终分析。
总体而言，有 60 例准父亲在受孕前短期使用 TNF 阻滞剂。其中 28 例记录了妊娠结局。我们没有发现与 TNF 阻断治疗和生育能力相关的流产或身体异常的任何记录；然而，我们确实发现有记录表明，TNF 阻断治疗甚至可以改善精子的活力和活力。这种改善可能是由于疾病活动度的降低。
已发表的数据表明，男性患者在受孕期间使用 TNF 阻滞剂不会增加不良妊娠结局的风险。此外，TNF 阻滞剂似乎不会降低男性生育能力。
